A multi-institution phase I/II Trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 702-706

  Kubota, Kaoru ^a,b   Sakai, Hiroshi ^c   Yamamoto, Nobuyuki ^d   Kunitoh, Hideo ^b,e   Nakagawa, Kazuhiko ^f   Takeda, Koji ^g   Ichinose, Yukito ^h   Saijo, Nagahiro ^a,f   Ariyoshi, Yutaka ⁱ   Fukuoka, Masahiro ^j  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ AICHI PREFECTURAL UNIVERSITY   (Japan)

^j KINKI UNIVERSITY   (Japan)

more..

Author keywords

Chemotherapy; Cisplatin; NSCLC (non small cell lung cancer); Phase I II trial; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEMATOCHEZIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHOCK; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77951813096     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ce3e22     Document Type: Article

References (19)

1. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel pluscisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-261.
2. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group. J Clin Oncol 2001;19:3210-3218.
3. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
4. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465.
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
7. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158. (Pubitemid 24026882)
8. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
9. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
10. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
11. Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755.
12. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
13. van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-2779.
14. Yamada Y, Hamaguchi T, Goto M, et al. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003;89:816-820.
15. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
18. Yamada Y, Saito H, Oie S, et al. Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice. Jpn J Cancer Chemother 1990;17:1327-1331.
19. Satouchi M, Kotani Y, Katakami N, et al. Randomized phase II study of two different schedules of gemcitabine and oral TS-1 in chemo-naive patients with advanced non-small cell lung cancer (NSCLC) (Meeting Abstracts). J Clin Oncol 2008;26:8103